Syndax Pharmaceuticals announced a new clinical collaboration with Genentech, a member of the Roche Group. As part of the collaboration, the two companies will evaluate the combination of Syndax’s entinostat, an oral, small molecule, class I HDAC inhibitor, and Genentech’s programmed cell death ligand 1 (PD-L1) blocking antibody, atezolizumab (TECENTRIQ), in patients with second-line hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+, HER2-) metastatic ...